Member Info for inanaco

whats 14% of 25 ? interesting that the "bias" to the debate puts it at 4 not 3

14% like it ... that is now the same as genexine as you have alluded ....

so based only on CR

three things "time" to CR
% of CR of the 25 can we double that to 28%
"immune response from the vaccine detected"

Now Ivy if you actually follow the post concerned

If you want my honest opinion (I know you probably don't lol) but I think Knowlesi is probably right about SCIB1 in it's current form. I can't ever see it getting to market or anybody paying to license it. That's mainly because as Inanaco alluded to yesterday, SCIB1+ is sitting there waiting to be developed and I can't see anybody paying to run a large randomised study with a vaccine that only works in 45% of the population when another is available that covers 90%.

"" That's mainly because as Inanaco alluded to yesterday, SCIB1+ is sitting there waiting to be developed ""

information i put on the BB was being used in a different argument hence the "red herring" i then followed up the "red herring" post with very strong data to support my objection ..

Logical fallacy
According to the Oxford English Dictionary, a red herring may be intentional, or unintentional; it is not necessarily a conscious intent to mislead. The expression is mainly used to assert that an argument is not relevant to the issue being discussed.

To explain in laymens terms ............ every time you have an immune response .. your Immune system leaves a "signature"

so you have specific T cells that can be detected against the vaccine epitopes
if the T cells "expand" = mount an immune response ......... a signature cytokine is detected

Keytruda responders have "exhausted T cells" that are being turned on and maybe of low affinity

The GP100 epitope part of the vaccine will help them to .. as it washes IFyn over them because its CD4 helper T cell

you then have the TPR2 CD8's of High Avidity ... supporting the low affinity exhausted T cells ..

the reason why you have poor t cells is because the cancer "escaped the immune response"

Keytruda only works on T cells ...

the "bar" set at 14% or 30% ... is statistics ... indeed i posted the important data from the trial ...
Its not just the 30% res-ponders .. its the "CR" responders and then its the time in treatment of that "CR" does SCIB1 give a second kick to patients that would have responded anyway to keytruda ... so a "keytruda partial responder becomes " "complete response " ... you have to look at the data that could be produced in far more detail .. because they can track every patient via blood work and scans

You could place HLA restrictions on the second Immunobody ... treating only the patients SCIB1 left behind .. Scancell owns the technology .. for both versions

on the 45% patient criteria .... allowing the min of 3 years to bring the mark 2 into the clinic I appreciate that is under a different Immunobody patent, plus at least 1 year in a phase 1 ... the mark 1 version is already 4 years ahead .. with predicted sales even of £500m would generate a £2b cash bonanza for £50m /70m expenditure . any deal with SCIB1 could include options on Mark 2

Red Herring

Bermuda
despite the fact that genexine and merck only have 28 patients with a 10 lead in ? how is it Merck will pay only for small numbers ?
scancell already has 35 "immune responses" which is what this is all about ..

https://www.lexology.com/library/detail.aspx?g=f9dda657-ab4d-4496-a891-772f48b8cc3d

you need to add 5 year to to the patent date ... even if we had used up the 5 years before approval, you would still get a further 7

Oh No ........... !! Black&decker have just launched a cordless electroporation device for £299 at B and Q hot off the press says nowless ...

Patent term extension, which partially compensates manufacturers for patent term lost to the premarket regulatory approval process, has enabled numerous products to maintain exclusivity beyond their original expiration dates, resulting in some cases in billions of dollars of additional revenues

These incentives include a partial tax credit for clinical trial expenditures, waived user fees, and eligibility for 7 years of marketing exclusivity [1].

SCIB1 has FDA Orphan status .... suggest you read up on it .. it creates exclusive markets

exactly bermuda

""For all we know they may have an excellent working relationship""

has an equal and opposite response ... "for all we know they might Not "

nothing wrong with "alternative views"

ATB

which patent ... ?

Glycans from scancell view are targets c7 like an epitope ... but way more complicated because your trying to get an immune response from a sugar .... not a protein ... T cells cannot lock onto sugars they hunt proteins .... but The unique and complex structures make glycans the most information dense biopolymers on earth ... so you have to find something that can lock onto a pathogen which the sugar can be hence use of an "the antibody" ... however glycans can lock onto proteins as well ...

but it gets far worse ... because Glycans can also interact with T cells .. !!

https://www.frontiersin.org/articles/10.3389/fimmu.2018.02754/full

headache ... enough

you have it now Ray ... at least i can point you into the correct area to study ...

https://youtu.be/SZIBFWmQqBc